Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips tells Proactive the company has made great progress towards commercialisation in a Phase 1C study of its topical Pan LOX inhibitor, achieving a well-tolerated safety profile and a marked change in scar composition. Importantly, the study’s results mark the first-ever proof that LOX inhibition reduces skin collagen, having achieved a 30% reduction in the scar’s collagen content.
Pharmaxis extends scarring collaboration after encouraging results
